IOVA News and Press, Iovance Biotherapeutics Inc. From 03/06/24

2024-03-06 04:42:00 ET Iovance Biotherapeutics (NASDAQ: IOVA) stock fell on Feb. 29, the day after it reported its fourth-quarter earnings, but that didn't stop Goldman Sachs analyst Andrea Tan from issuing a sunny outlook, raising her price target for the stock from $19 to $21....

SAN CARLOS, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that t...

2024-03-02 06:50:00 ET Iovance Biotherapeutics (NASDAQ: IOVA) has been one of the hottest healthcare stocks in 2024. It has already doubled in value and investors are hopeful that there could still be more upside left for the shares now that regulators have approved one of its treat...

2024-02-29 17:47:00 ET Iovance Biotherapeutics (NASDAQ: IOVA) , one of the more high-flying biotech stocks of late, fell earthward in trading on Thursday. This was a direct consequence of its latest quarterly figures and operational update that were published after hours on Wednesda...

2024-02-29 05:51:00 ET Some investors are attracted to small biotech stocks because of their potential for explosive returns. It's not uncommon for these stocks to go parabolic after positive news is announced. That's exactly what happened to Iovance Biotherapeutics (NASDAQ: IOVA)...

Amtagvi™ (lifileucel) U.S. Launch Fully Underway Following U.S. Food and Drug Administration (FDA) Approval as the First and Only One-Time, Individualized T cell Therapy for a Solid Tumor Cancer Amtagvi Regulatory Submissions on Track in the European Union, United Kingdom, and Cana...

SilverBow Resorces Inc. (SBOW) is expected to report $2.36 for Q4 2023 FAT Brands Inc. Class B Common Stock (FATBB) is expected to report for quarter end 2023-12-31 Ecovyst Inc. (ECVT) is expected to report $0.2 for Q4 2023 MYR Group Inc. (MYRG) is expected to report $1.41 for Q4 2023...

2024-02-26 05:39:00 ET Investors looking for stocks that can produce swift and dramatic gains recently found what they wanted with Iovance Biotherapeutics (NASDAQ: IOVA) . Over the past three months, shares of the cancer drug developer nearly tripled in value. Despite an already...

2024-02-25 05:01:00 ET Iovance Biotherapeutics (NASDAQ: IOVA) just reached a huge milestone -- and investors have flocked to the stock, helping it to soar more than 70% in less than a week. What's the big news? The biotech company scored its first regulatory approval, from the U...

2024-02-23 15:00:00 ET More on the markets SPDR S&P 500 ETF And Invesco QQQ Trust: Almost All Investors Are Crowded Into The Same Side Of The Boat SPY: The U.S. Is Positioned To Expand Its Global Dominance S&P 500: Correction In Progress, Deeper Selloff Expec...